Empagliflozin
Brand: Jardiance (US/EU) / Empa (IN) / Empaglo (BD)
Antidiabetic
SGLT2 inhibitor
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 1.5 h |
| Bioavailability | 78 % (approx) |
| Protein Binding | 86 % |
| Volume of Distribution | 1.3 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | no |
| Notes | Initiation typically requires eGFR ≥45 for glycemic effect (lower thresholds for HF/CKD indications per guidelines). |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Genital mycotic infections, polyuria, volume depletion, rare euglycemic DKA
Contraindications:
Dialysis
Precautions:
Educate on DKA sick-day rules; pause before major surgery/acute illness; monitor volume status in elderly/diuretics